Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-9 of 9 for your search:
Drug:
nilutamide
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Total Androgen Blockade With or Without Pelvic Irradiation in Patients With Locally Advanced Adenocarcinoma of the Prostate
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
Under 80
Sponsor:
NCI
Protocol IDs:
CAN-NCIC-PR3
, CALGB-9593, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, T94-0110, NCT00002633, PR3
2.
Phase III Study of Chemo/Hormonal Therapy vs Androgen Ablation Alone as Initial Therapy in Patients With Unresectable/Metastatic Adenocarcinoma of the Prostate
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
no age specified
Sponsor:
NCI
Protocol IDs:
MDA-DM-95231
, NCI-G96-1044, NCT00002855
3.
Phase III Randomized Study of Intermittent Versus Continuous Androgen Suppression in Patients With Prostate-Specific Antigen Progression in the Clinical Absence of Distant Metastases After Prior Radiotherapy for Prostate Cancer
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
CAN-NCIC-PR7
, SWOG-JPR7, ICR-CTSU-JPR7, JPR7, NCT00003653, PR7
4.
Phase III Randomized Double-Blind Trial of Antiandrogen Therapy with Anandron plus the LHRH Agonist Zoladex vs Placebo in Patients with Unresectable Hepatocellular Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
postpubertal
Sponsor:
Protocol IDs:
EORTC-40861
5.
Phase III Randomized Comparison of Leuprolide/Anandron vs Leuprolide/Placebo in Patients with Stage D2 Carcinoma of the Prostate
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
40 to 85
Sponsor:
Protocol IDs:
FCCC-86814
, NCI-V87-0282
6.
Phase II Randomized Study of Vaccine Containing Recombinant Vaccinia-Prostate-Specific Antigen (PSA) Admixed With rV-B7.1 Plus Recombinant Fowlpox-PSA Vaccine, Sargramostim (GM-CSF), and Interleukin-2 Versus Nilutamide Alone in Patients With Hormone-Refractory Prostate Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-00-C-0137
, MB-NAVY-99-04, NCI-T99-0097, T99-0097, NCT00020254
7.
Phase II Study of Early Estramustine, Etoposide, and Paclitaxel With Combined Androgen Blockade Therapy in Patients With High-Risk Metastatic Adenocarcinoma of the Prostate
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
SWOG-S0032
, S0032, NCT00028769
8.
Phase II Randomized Study of Combined Androgen Ablation With Versus Without Adjuvant Docetaxel and Estramustine in Patients With Androgen-Dependent Recurrent Prostate Cancer
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MDA-DM-99224
9.
Phase I Study of Limited Androgen Ablation and Antiandrogen Therapy Followed by Temsirolimus in Patients With Biochemically Relapsed Prostate Cancer After Prostatectomy and/or Radiotherapy
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
MDA-2007-0025
, 7862, 2007-0025, NCT00512668
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute